The Role of Aβ Peptides in Alzheimers Disease
Abstract
The Abeta peptide has been identified as central to the onset and development of Alzheimer's disease (AD) and several hypotheses about toxicity involving Abeta peptides have been proposed including mechanisms of oxidative stress and disruption of calcium homeostasis. The biology, structure and physical properties of Abeta peptides are discussed, as well as existing therapeutics and future strategies for the treatment of AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reducing the amount of amyloid-beta has been a major target in the development of Alzheimer's disease therapeutics.
“As such, reducing the amount of Aβ has been a major target in the development of AD therapeutics [30,31,32].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [32]
Cites
Anti‐Inflammatory Drugs in the Fight against Alzheimer's Diseasea
McGeer, P. L., & McGeer, E. G. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34421.x · Cited by 123 · see citing works
Donepezil in the treatment of Alzheimer's disease
Rocca, P., Cocuzza, E., Marchiaro, L., & Bogetto, F. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00283-4 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works
- Authors
- Tickler, A., Wade, J., & Separovic, F.
- Affiliations
- The University of Melbourne (AU)
- Venue
- Protein & Peptide Letters
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-08-01
- Volume
- 12
- Issue
- 6
- Pages
- 513-519
- ISSN
- 0929-8665 (ISSN-L)
- OpenAlex
- W2091098759
- Cited by
- 23
- References
- 2
- Citations by year
- 2022: 2 · 2020: 1 · 2019: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2012: 2
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Protein and Peptide Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, oxidative stress, calcium homeostasis, Alzheimer's disease therapeutics
- MeSH terms
- Alzheimer Disease, Humans, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Protein Structure, Quaternary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
